Erich Reinhardt will resign as CEO of Siemens Healthcare, effective April 30, following the discovery of a fund to pay for bribes for foreign contracts.
Reinhardt, who has never been linked to the investigation, will continue to serve the Erlangen, Germany-based company as a consultant.
Siemens expects to name 49-year-old Jim Reid-Anderson, previously the CEO of Siemens Healthcare's Diagnostics Division, as Reinhardt's successor.
In a written statement following the resignation announcement, Siemens chairman Gerhard Cromme said there is "no doubt about the personal integrity of Professor Reinhardt. Based on all that we know, he was not personally involved in any questionable activities. We have determined, however, that there was unacceptable behavior in the former Medical Solutions Group."
Reinhardt became head of Siemens Medical Solutions in 1994 and joined the managing board of Siemens AG of Berlin in September 2001. He has served as CEO of the newly created Healthcare sector since January.
Reid-Anderson previously served as executive vice president and chief financial officer of the former Dade Behring company in 1996 and was named CEO in 2000. Siemens acquired Dade Behring last year.
Siemens Healthcare last year was stung by the discovery of a fund through which bribes were paid to obtain foreign contracts. The Healthcare group acknowledged the existence of funds worth approximately $2.1 billion and agreed last October to pay a fine of $317 million.
Siemens also is the subject of an investigation by the U.S. Securities and Exchange Commission because of the developments in Germany.
Related Reading
Siemens completes U.K. Artis install, April 23, 2008
Siemens lands U.K. order, April 21, 2008
Siemens wins Scottish FFDM contract, April 17, 2008
Siemens opens new training center, April 15, 2008
Siemens launches wireless monitoring service, April 9, 2008
Copyright © 2008 AuntMinnie.com
![Overview of the study design. (A) The fully automated deep learning framework was developed to estimate body composition (BC) (defined as subcutaneous adipose tissue [SAT] in liters; visceral adipose tissue [VAT] in liters; skeletal muscle [SM] in liters; SM fat fraction [SMFF] as a percentage; and intramuscular adipose tissue [IMAT] in deciliters) from MRI. The fully automated framework comprised one model (model 1) to quantify different BC measures (SAT, VAT, SM, SMFF, and IMAT) as three-dimensional (3D) measures from whole-body MRI scans. The second model (model 2) was trained to identify standardized anatomic landmarks along the craniocaudal body axis (z coordinate field), which allowed for subdividing the whole-body measures into different subregions typically examined on clinical routine MRI scans (chest, abdomen, and pelvis). (B) BC was quantified from whole-body MRI in over 66,000 individuals from two large population-based cohort studies, the UK Biobank (UKB) (36,317 individuals) and the German National Cohort (NAKO) (30,291 individuals). Bar graphs show age distribution by sex and cohort. BMI = body mass index. (C) After the performance assessment of the fully automated framework, the change in BC measures, distributions, and profiles across age decades were investigated. Age-, sex-, and height-adjusted body composition reference curves were calculated and made publicly available in a web-based z-score calculator (https://circ-ml.github.io).](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/05/body-comp.XgAjTfPj1W.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
